Search Results - TherapeuticArea+%3e+Oncology

564 Results

Sort By:

Compositions and Methods for Producing Dendritic Cell-based Vaccines with Enhanced Efficacy

Summary: The National Cancer Institute (NCI) is seeking research co-development partners and/or licensees for NCI’s compositions and methods to enhance the efficacy of dendritic cell (DC)-based cancer vaccines. Description of Technology: Current dendritic cell (DC)-based cancer vaccines are limited by impaired DC function due to cancer-driven...

Published: 7/15/2025 | Inventor(s): Jay Berzofsky, Shweta Tiwary

Keywords(s):

Category(s): TherapeuticArea > Oncology, TherapeuticArea > Immunology, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing

Enhanced Tumor Reactivity of T Cells Lacking SIT1, LAX1 or TRAT1

Summary: The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is actively seeking potential licensees interested in further developing these inhibitory transmembrane adapter proteins as targets for T-cell immunotherapy for the treatment of cancer, infectious diseases, and autoimmune diseases. Description of Technology: Cellular...

Published: 7/14/2025 | Inventor(s): Paul Love, Avik Dutta

Keywords(s):

Category(s): Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Immunology

Vascularized Thyroid-on-a-Chip for Personalized Drug Screening and Disease Modeling

This technology includes a micro-engineered “thyroid-on-a-chip” that combines human thyroid organoids with integrated micro-vasculature to replicate the gland’s native blood flow and 3-D architecture, enabling rapid, patient-specific drug screening. By permitting real-time perfusion of nutrients, hormones, and immune cells, the platform...

Published: 7/15/2025 | Inventor(s): Anagha Rama Varma, Parnika Kant, Kaitlyn Sadtler, Parinaz Fathi, Nicole Morgan, Paniz Rezvan Sangsari, Madison Daminato

Keywords(s):

Category(s): Application > Diagnostics, Application > Medical Devices, Application > Research Materials, Application > Therapeutics, ResearchProducts > Human Cell Lines, ResearchProducts > Research Equipment, TherapeuticArea > Endocrinology, TherapeuticArea > Immunology, TherapeuticArea > Metabolic Disease, TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing

Synergistic Interactions for Improved Cancer Treatment

Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees to develop hetIL-15 in combination with other agents, such as PPARa agonists (Fenofibrate), FLT3 inhibitors (quizartinib), IL-12, or chemotherapy into a therapeutic for cancer. Description of Technology: Immunotherapy has emerged as a promising treatment...

Published: 6/27/2025 | Inventor(s): Barbara Felber, George Pavlakis, Sevasti Karaliota, Dimitrios Stellas

Keywords(s):

Category(s): TherapeuticArea > Immunology, TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing

Establishment and characterization of the A 1847 human ovarian carcinoma line

Summary: The National Cancer Institute (NCI) seeks licensees for a tumorigenic cell line, A1847, from a patient with metastatic ovarian cancer. As a BRCA1 deficient cell line, it serves as a model to researchers studying cell cycle regulation, tumor suppression and effective drugs aiding in repair of DNA damage. Description of Technology: Mutations,...

Published: 6/27/2025 | Inventor(s): Stuart Aaronson, Nelson Ellmore (Estate)

Keywords(s):

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Licensing, Application > Research Materials

Angubindin-1 Peptide for Transient Blood-Brain Barrier Opening to Boost Chemotherapy in Malignant Glioma

This technology includes a first-in-class synthetic peptide, angubindin-1, designed to temporarily relax the blood-brain barrier (BBB)—the tightly sealed network of brain blood vessel cells that normally blocks most drugs—from the inside. By binding the tricellular tight-junction protein angulin-1/LSR, the peptide creates a reversible “molecular...

Published: 6/13/2025 | Inventor(s): Sadhana Jackson

Keywords(s):

Category(s): Application > Therapeutics, TherapeuticArea > Neurology, TherapeuticArea > Oncology, Collaboration Sought > Licensing

First in class Small Molecule Agonists of the mammalian Relaxin family receptor 1 (RXFP1) and use in treatment of cancer, fibrotic, and vascular disorders (HHS Ref No. E-145-2024-0-US-02)

It is well documented in literature that activation of RXFP1 by relaxin induces: 1) up-regulation of the endothelin system which leads to vasodilation; 2) extracellular matrix remodeling through regulation of collagen deposition, cell invasiveness, proliferation, and overall tissue homeostasis; 3) a moderation of inflammation by reducing levels of inflammatory...

Published: 5/30/2025 | Inventor(s): Juan Marugan, Mark Henderson, Kenneth Wilson, Wenwei Huang, Wenjuan Ye, Noel Southall, Jiankang Jiang, Khalida Shamim, Bing Li, Alexander Agoulnik, Abhijeet Kapoor, Joshua Hutcheson, Ana Cabrera, Irina Agoulnik

Keywords(s):

Category(s): Application > Therapeutics, Application > Research Materials, TherapeuticArea > Oncology, TherapeuticArea > Cardiology, TherapeuticArea > Pulmonology, TherapeuticArea > Dermatology, TherapeuticArea > Reproductive Health, TherapeuticArea > Geriatrics

Next-Generation 5-HT-2B Serotonin-Receptor Antagonists for Anti-Fibrotic & Cardiopulmonary Therapy

This technology includes a family of small-molecule antagonists that selectively block the 5-HT2B serotonin receptor—an upstream driver of tissue-remodeling—to address fibrotic, cardiopulmonary and related disorders. Built on a conformationally-locked “(N)-methanocarba” nucleoside scaffold, the compounds show nanomolar potency,...

Published: 5/14/2025 | Inventor(s): Kenneth Jacobson, Dilip Tosh

Keywords(s):

Category(s): Application > Research Materials, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Cardiology, TherapeuticArea > Dermatology, TherapeuticArea > Immunology, TherapeuticArea > Metabolic Disease, TherapeuticArea > Oncology, TherapeuticArea > Pulmonology, TherapeuticArea > Respiratory

Fluorophthalimides as Anti-inflammatory Agents for Systemic and Neurodegenerative Disorder

Summary: The National Institute on Aging (NIA) seeks research co-development partners and/or licensees for the pre-clinical and clinical development of the compounds as anti-inflammatory therapeutics for systemic and neurodegenerative disorders. Description of Technology: Numerous systemic, as well as neurological disorders, have a hallmark inflammatory...

Published: 6/27/2025 | Inventor(s): Nigel Greig, Weiming Luo, David Tweedie, Michael Scerba, Daniela Lecca, Shih Chang Hsueh

Keywords(s):

Category(s): TherapeuticArea > Neurology, TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics

In-vivo System to Interrogate the Functions of Mucous Membranes and Identify Mucin/Glycan Mimetics and JAK/STAT Inhibitors for the Treatment of Diseases of the Oral Cavity and Digestive Tract

This technology includes a Drosophila mutant strain that can be used as an in vivo model for diseases of the oral cavity and digestive tract (Sjogren's syndrome, colitis, colon cancer, inflammatory bowel disease), where the mucous membrane is disrupted or non-functional. This mutant lacks a mucous membrane and displays epithelial cell damage, uncontrolled...

Published: 12/26/2024 | Inventor(s): Liping Zhang, Kelly Ten Hagen

Keywords(s): FUNCTIONS, IDENTIFY, Inhibitors, Interrogate, Jak/STAT, MEMBRANES, MIMETICS, Mucin/glycan, Mucous, System, Vivo, VPXXXX, WIXXXX, XEXXXX

Category(s): TherapeuticArea > Oncology, TherapeuticArea > Infectious Disease, TherapeuticArea > Ophthalmology, TherapeuticArea > Endocrinology, TherapeuticArea > Dental, Application > Therapeutics, Application > Research Materials, TherapeuticArea > Cardiology

1 2 3 4 5 6 7 8 9 10 ...